SG52475A1 - Cytosine deaminsae negative selection system for gene transrer techniques and therapies - Google Patents

Cytosine deaminsae negative selection system for gene transrer techniques and therapies

Info

Publication number
SG52475A1
SG52475A1 SG1996005053A SG1996005053A SG52475A1 SG 52475 A1 SG52475 A1 SG 52475A1 SG 1996005053 A SG1996005053 A SG 1996005053A SG 1996005053 A SG1996005053 A SG 1996005053A SG 52475 A1 SG52475 A1 SG 52475A1
Authority
SG
Singapore
Prior art keywords
gene
therapies
cytosine
deaminsae
transrer
Prior art date
Application number
SG1996005053A
Other languages
English (en)
Inventor
Craig A Mullen
R Michael Blaese
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of SG52475A1 publication Critical patent/SG52475A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Devices For Checking Fares Or Tickets At Control Points (AREA)
  • Brushes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG1996005053A 1991-07-03 1992-06-30 Cytosine deaminsae negative selection system for gene transrer techniques and therapies SG52475A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/725,076 US5358866A (en) 1991-07-03 1991-07-03 Cytosine deaminase negative selection system for gene transfer techniques and therapies

Publications (1)

Publication Number Publication Date
SG52475A1 true SG52475A1 (en) 1998-09-28

Family

ID=24913069

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005053A SG52475A1 (en) 1991-07-03 1992-06-30 Cytosine deaminsae negative selection system for gene transrer techniques and therapies

Country Status (12)

Country Link
US (2) US5358866A (el)
EP (1) EP0595873B1 (el)
JP (1) JP3386461B2 (el)
AT (1) ATE191505T1 (el)
AU (1) AU667820B2 (el)
CA (1) CA2112395C (el)
DE (1) DE69230882T2 (el)
DK (1) DK0595873T3 (el)
ES (1) ES2152929T3 (el)
GR (1) GR3033909T3 (el)
SG (1) SG52475A1 (el)
WO (1) WO1993001281A1 (el)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
US6555370B1 (en) * 1990-11-13 2003-04-29 Immunex Corporation Bifunctional selectable fusion genes
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
JPH07506370A (ja) * 1992-05-01 1995-07-13 アメリカ合衆国 バイスタンダー作用による殺腫瘍療法
EP0804590A1 (en) * 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
DE69524740T2 (de) * 1994-05-02 2002-08-14 University Of Washington, Seattle Thymidin-kinase-mutanten
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5856153A (en) * 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
AU7525496A (en) * 1995-10-23 1997-05-15 Betagene, Inc. Methods and compositions comprising glut-2 and glut-2 chimeras
WO1997029201A2 (de) * 1996-02-07 1997-08-14 Max-Delbrück-Centrum für Molekulare Medizin Retroviraler vektor für den gentransfer eines il6-antagonisten in humane hämatopoetische stammzellen
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
CN1303436A (zh) * 1998-02-19 2001-07-11 圣朱迪儿童研究医院 致敏和抑制人肿瘤细胞生长的组合物和方法
GB9810752D0 (en) * 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
US7186409B2 (en) * 1998-08-14 2007-03-06 The Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
FR2794025A1 (fr) * 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
US8716558B2 (en) 1999-06-30 2014-05-06 Marker Gene Technologies, Inc. Method of altering glycosylation of proteins in response to nojirimycin glucuronide in a plant cell expressing glucuronidase
US6656917B1 (en) * 1999-06-30 2003-12-02 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
US7393526B2 (en) * 2000-03-15 2008-07-01 Children's Medical Center Corporation Systemic gene delivery vehicles for the treatment of tumors
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
DK1911837T3 (da) * 2000-09-28 2011-08-29 Bioriginal Food & Science Corp FAD5-2 fedtsyredesaturasefamiliemedlem og anvendelser deraf
EP1264891A1 (en) * 2001-05-31 2002-12-11 Plant Research International B.V. Modification of plant genomes by inducible site-specific recombination of transgenes
DE60237696D1 (de) * 2001-08-01 2010-10-28 Univ Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
ATE405658T1 (de) * 2002-07-26 2008-09-15 Basf Plant Science Gmbh Neue selektionsverfahren
US20040149174A1 (en) * 2003-02-05 2004-08-05 Mbt Holding Ag Accelerating admixture for concrete
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
PL1649023T3 (pl) 2003-07-21 2009-01-30 Transgene Sa Polipeptyd o podwyższonej aktywności deaminazy cytozyny
ES2340038T3 (es) * 2003-11-14 2010-05-28 Genvec, Inc. Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
AU2005224324B2 (en) * 2004-03-17 2009-12-24 Basf Plant Science Gmbh Improved constructs for marker excision based on dual-function selection marker
US20080039328A1 (en) * 2004-03-17 2008-02-14 Basf Plant Science Gmbh Post Harvest Control of Genetically Modified Crop Growth Employing D-Amino Acid Compounds
KR101169109B1 (ko) 2004-05-26 2012-07-26 싸이오서스 테라퓨틱스 엘티디. 암 치료에 사용하기 위한 키메릭 아데노바이러스
EP2166103B1 (en) 2004-08-02 2013-05-22 BASF Plant Science GmbH Method for isolation of transcription termination sequences
ATE552343T1 (de) 2005-04-19 2012-04-15 Basf Plant Science Gmbh Endosperm-spezifische expression und/oder expression in keimenden embryos monokotyledoner pflanzen
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
EP2360473A1 (en) 2005-08-22 2011-08-24 Cornell Research Foundation Compositions and methods for analyzing protein interactions
AU2008214568B2 (en) 2007-02-16 2013-04-18 Basf Plant Science Gmbh Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
EP3502256A3 (en) 2008-09-26 2019-09-25 Tocagen Inc. Recombinant vectors
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
IN2014MN01298A (el) * 2011-12-21 2015-07-03 Cj Cheiljedang Corp
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
ES2661132T3 (es) 2013-10-25 2018-03-27 Psioxus Therapeutics Limited Adenovirus oncolíticos armados con genes heterólogos
WO2015089280A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
DK3129037T3 (da) 2014-04-10 2020-02-03 Transgene Onkolytiske koppevirusvektorer
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
WO2018041838A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102371151B1 (ko) 2020-03-13 2022-03-07 주식회사 큐로셀 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies

Also Published As

Publication number Publication date
DK0595873T3 (da) 2000-07-10
EP0595873B1 (en) 2000-04-05
CA2112395A1 (en) 1993-01-21
DE69230882T2 (de) 2000-11-09
ES2152929T3 (es) 2001-02-16
WO1993001281A1 (en) 1993-01-21
JPH07501925A (ja) 1995-03-02
AU2295992A (en) 1993-02-11
EP0595873A1 (en) 1994-05-11
US5624830A (en) 1997-04-29
US5358866A (en) 1994-10-25
GR3033909T3 (en) 2000-11-30
EP0595873A4 (en) 1994-12-07
ATE191505T1 (de) 2000-04-15
JP3386461B2 (ja) 2003-03-17
DE69230882D1 (de) 2000-05-11
AU667820B2 (en) 1996-04-18
CA2112395C (en) 2008-04-22

Similar Documents

Publication Publication Date Title
SG52475A1 (en) Cytosine deaminsae negative selection system for gene transrer techniques and therapies
EP0500917A4 (en) Recombinant herpes simplex viruses vaccines and methods
DK0506945T3 (da) Fremgangsmåde til genoverførsel under anvendelse af retrotransposoner
ES8705036A1 (es) Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana
EP0088195A3 (en) Messenger rna, production and use thereof
CA2182303A1 (fr) Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
AU681705B2 (en) Endosomolytically active particles
AU7335296A (en) Recombinant sendai virus
HK1018287A1 (en) (-)-strand rna virus vector having autonomously replicating activity
AU8067698A (en) Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
AU6149596A (en) Tumor- or cell-specific herpes simplex virus replication
Litzkas et al. Efficient transfer of cloned DNA into human diploid cells: protoplast fusion in suspension
NZ304076A (en) cell culture methods to produce neural cells population with an introduced positive selective marker
AU4307197A (en) Herpesvirus saimiri as viral vector
IL148360A0 (en) A herpes viral mutant and pharmaceutical compositions containing the same
Doersen et al. Cytoplasmic inheritance of erythromycin resistance in human cells.
EP0326127A3 (en) Infectious bovine rhinotracheitis virus insertion mutants, vaccins containing same, and methods for the production and use of same
MX9707910A (es) Vector viral recombinante inducible por la glucosa.
NZ196643A (en) Application of genetic engineering techniques to autotrophic or methylotrophic bacteria;composite plasmid derived from r300b
IL118942A0 (en) Avirulent herpetic viruses useful as tumericidal agents and vaccines
Mullen et al. Cytosine deaminase negative selection system for gene transfer techniques and therapies
EP1015560A4 (en) CHANGED SMALL RNA VIRUSES
ES2000404A6 (es) Un metodo de transformacion del actinomiceto streptomyces wadayamensis
Coleman Comparison of the abilities of free and membrane-bound polyribosomes isolated from exponential-phase cells of Bacillus amyloliquefaciens to incorporate amino acids into protein.
WO2000008192A3 (en) Herpesviral vectors for gene delivery